Teikoku Pharma USA Email Format

Pharmaceutical ManufacturingUnited States11-50 Employees

Teikoku Pharma USA is a United States–based pharmaceutical manufacturer focused on developing and commercializing postoperative pain therapies, including TPU-006, a non-opioid patch. The company announced positive topline results from Phase 2 testing of TPU-006 for abdominoplasty and has since received FDA Fast Track Designation for this product. In 2015 it entered into an exclusive U.S. licensing agreement with Eagle Pharmaceuticals to market Docetaxel Injection, illustrating a broader portfolio beyond pain management.

The company serves healthcare providers and hospitals seeking non-opioid approaches to postoperative pain, as well as partners for oncology injectables through licensing arrangements. Based in the United States, Teikoku Pharma USA positions itself in the pharmaceutical manufacturing space with a focus on specialty therapies and strategic collaborations.

Sign up for free to view info

Company overview Employee directory